Palliative and hospice care programs can decrease the burden of symptoms, reduce hospitalization, and improve end-of-life care. 3 There are limited data on the utilization of hospice in cirrhosis; a population that has received limited attention from the palliative care community. Thus, we aimed to identify trends and variations in both places of death and hospice utilization 4 in cirrhosis.
Methods
We used the US National Center for Health Statistics mortality records through the Wide-Ranging Online Data for Epidemiologic Research platform. This registry contains data on all deaths of US residents based on death certificates and serves as the primary source to track mortality rates and causes of death in the United States. 5, 6 We selected patients (18 y) who had cirrhosis as the underlying cause of death from January 2003 to December 2015. In accordance with the National Center for Health Statistics definitions, cirrhosis was defined by International Statistical Classification of Diseases, 10th revision (ICD-10) codes K70.3 (alcoholic cirrhosis of liver) and K74.6 (other and unspecified cirrhosis of liver). 6 The chisquared test was used to compare the proportion of cirrhosis deaths among groups, and the Spearman correlation test was used to identify trends (year vs percentage of death). The proportion of hospice deaths was compared between patients who died of cirrhosis vs those who died of selected malignancies (pancreas, ICD-10 code C25; esophagus, ICD-10 code C15; colon, ICD-10 code C18; lung, ICD-10 code C34; and breast, ICD-10 code C50).
Results
A total of 340,380 cirrhosis deaths occurred during the study period. Cirrhosis mortality increased from 10.3 (2003) to 13.7 (2015) per 100,000. Of the cirrhosis deaths, 49.1% occurred as inpatients, 3.1% in the outpatient/emergency room, 24.1% at home, 12.3% in nursing homes or long-term care, 6.4% hospice, and 5.0% occurred in other locations (dead on arrival to hospital, other public or unknown location).
Between 2003 and 2015, there was a decrease in the percentage of cirrhosis deaths in the inpatient setting (55.8% to 44.8%; P trend < .001) and nursing homes/long-term care units (12.8% to 11.8%; P trend < .001), accompanied by an increase in deaths at home (21.6% to 26.1%; P trend < .001) and in hospice (0.2% to 11.6%; P trend < .001) (Figure 1) .
Hospice deaths were more likely to occur among white compared with black patients and other minorities (6.7% vs 4.4% vs 3.1%, respectively; P < .001) and marginally higher in female compared with male patients (6.8% vs 6.2%, respectively; P < .001).
Mortality rates for cancers per 100,000 were as follows: pancreas (15.5), esophagus (6.0), colon (18.5), lung (67.8) and female breast (34.3) compared with 11.3 for cirrhosis. Hospice utilization remained lower in cirrhosis (6.4%) compared with cancers: pancreas (8.5%; P < .001), esophagus (7.6%; P < .001), colon (7.3%; P < .001), lung (7.1%; P < .001), and breast (7.4%; P < .001).
Discussion
Because of the availability of liver transplantation, pursuing curative efforts creates uncertainty about the timing and nature of interventions, which may be associated with delays in palliative and hospice care involvement in patients with cirrhosis.
Despite the low percentage of hospice deaths among patients who died of cirrhosis, there was an increasing trend in hospice utilization at the end of life among these patients. However, the majority of patients with cirrhosis were institutionalized at the time of death, possibly suggesting suboptimal end-of-life care and lack of advance care planning.
The reasons for low utilization of hospice among patients with cirrhosis remain speculative. The current prognostic scores (eg, Model for End-stage Liver Disease and Child-Pugh) are not being used in predicting hospice eligibility in patients with cirrhosis. 7 To increase hospice care utilization, it is necessary to develop strategies to define the needs and expectations of patients with cirrhosis. Furthermore, developing effective clinical scores to predict the 6-month mortality in cirrhotic patients could help identify hospice eligibility and improve utilization.
It is possible that racial disparities in access to health care explain the variations in hospice care. Cultural differences also may play a role in determining the preferred places of death among patients with cirrhosis. 8 Limitations for this study included an inaccuracy of ICD-10 codes in identifying patients with cirrhosis, which may have been underestimated in our study. We also lacked data on utilization of home hospice care and inpatient palliative care services, which may have skewed our data.
In conclusion, in-patient cirrhosis-related deaths have decreased over time with an increase in home and hospice deaths. Despite that, only a minority of patients with cirrhosis died in hospice in the United States. Hospice utilization in patients with cirrhosis remains lower than in those who die of major cancers. 
